



---

## Article submission received

1 pesan

---

<editorial@f1000research.com>  
Kepada: andrianto@fk.unair.ac.id

Rab, 26 Mei 2021 pukul 13.28

Dear Andrianto

Thank you for submitting your manuscript:

**Mesenchymal Stem Cell Therapy Efficacy in COVID-19 Patients: A systematic review and meta-analysis**  
Andrianto A *et al.*

**Funders:** you have stated during the submission process that this work has been funded by:  
Indonesian Endowment Fund for Education (LPDP)

**As of 1st September 2020, Article Processing Charges (APCs) on F1000Research are based on article type rather than article length. Charges are payable once the article has been accepted for publication. A full explanation of the price transparency breakdown for the article type categories is available [here](#).**

### WHAT WE DO NEXT

**Before accepting your article:** we will check content suitability, readability and manuscript format; adherence to ethical standards for the type of study; that the underlying data have been supplied (where appropriate); and that there is sufficient detail to enable others to replicate the study (if applicable).

**Before publishing your article:** if we accept your article, we will be in touch as soon as possible with any issues that need addressing. You will then receive a final proof of your article for approval, prior to publication.

### WHAT YOU NEED TO DO NEXT

Before doing anything else, we need you to suggest **at least 5** suitable reviewers to peer review your manuscript following publication (in accordance with our [publishing model](#)), should it be accepted. We ask that authors do not contact reviewers directly about the peer review process. We will need your reviewer suggestions before we can publish the article so we recommend identifying them now via your [Suggest Reviewers](#) page for this article. You can also access this page via the article's record at [My Research >> Submissions](#).

Please quote the article number 53825 in any correspondence.

Kind regards

The F1000Research Team

**Press releasing articles:** Please avoid promoting articles in the media until the article has passed the [open peer review process](#). Promotion on social media is encouraged once the article has been published; please ensure the full citation is included, as this contains the peer review status. F1000Research should be cited as the source of these articles with a link to the article.

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Do not delete (filing code): F1KR00CDE F1R-VER57248-A (end code)



---

## Your article 53825 is now accepted

1 pesan

---

<editorial@f1000research.com>  
Kepada: andrianto@fk.unair.ac.id

Rab, 15 Sep 2021 pukul 15.13

Dear Andrianto,

**Mesenchymal stem cell therapy efficacy in COVID-19 patients: A systematic review and meta-analysis**

Andrianto A, Cempaka Sari DKS, Al Farabi MJ, Yusrizal T and Hermawan HO

We have now accepted your article for publication in F1000Research. It will be sent to the typesetters and a member of the Production team will send you a proof in due course.

One of our editorial team will be assisting you with the peer review process of your article, and will be your main contact once the article is published.

Best wishes,

Lisa  
The Editorial Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Do not delete (filing code): F1KR00CDE F1R-VER57248-A (end code)



---

## Manuscript 53825 conditionally accepted for publication

1 pesan

---

<editorial@f1000research.com>  
Kepada: andrianto@fk.unair.ac.id

Sen, 7 Jun 2021 pukul 22.13

Dear Andrianto,

### **Mesenchymal Stem Cell Therapy Efficacy in COVID-19 Patients: A systematic review and meta-analysis**

Andrianto A, Cempaka Sari DKS, Al Farabi MJ, Yusrizal T and Hermawan HO

Thank you for your submission to F1000Research. We have noted a few issues with your manuscript (below) – once these are addressed we will be pleased to accept your article for publication.

**Methods:** Please provide more detail in your Methods. Please bear in mind that reviewers and readers must be exactly able to recreate your study from the level of detail that you give. Track Changes provide comments in the manuscript but these are not exhaustive.

**Content:** Please provide the version number and a URL or citation for all software used in the study.

Please provide citations and explain abbreviations where indicated.

**PRISMA guidelines:** We endorse the PRISMA checklist for reporting systematic reviews. Please ensure that you have fully adhered to the [PRISMA reporting guidelines](#). Track changes in the document provide some queries relating to the checklist, but these are not exhaustive. Please also include a completed PRISMA checklist as *extended data* and the flow diagram. Please ensure that the flow diagram is the 2020 version, we noticed that the flow diagram you have provided as Figure 1 is from 2009.

We ask that authors submit their underlying/extended data to an online repository. More information can be found on [our data guidelines page](#). When submitting data to an online repository, please ensure you create a DOI, which will be stated and cited in the Data availability (Reporting guidelines) section of the manuscript. Please include the name of the repository and the DOI in the Data availability section, along with the license the data is held under (please make sure that you choose a license when submitting your data to a repository – we would strongly suggest a CC0 license).

Please also note that each dataset mentioned in the article, including the PRISMA reporting checklist in the Data availability statement, must be referenced using a formal data citation.

**Competing interests:** Please confirm that you have no competing interests to disclose.

**Grant information:** Please provide details of the grant you received in this section of the manuscript.

**References:** Only published journal articles, books, book chapters and abstracts (including pre-prints) should be included in the reference list. We notice some links to internet pages in the references; weblinks should not be included in the reference list but rather cited in the main text. Please make these changes.

**Figures:** Please provide the figures as separate files. Please send these as attachments in response to this email. The figures should be deleted from the main text and the figure titles should remain at the end of the manuscript where we have placed them.

Please can you expand the titles of your figures. Please bear in mind that the title should be sufficiently detailed so that the figure stands alone from the main text. Consider including additional detail because without this the reader will need to refer to the main text to understand the figure. Please also explain any abbreviations and symbols, if applicable.

Please ensure that you refer to each figure in the main text of the article; we noticed that the figures are not mentioned in the text. The figures should be mentioned in order.

**Tables:** The tables should be placed at the end of the manuscript rather than within the main text. We have done this for you.

We noticed that you have not referred to your tables in the main text of the article. Please ensure that you refer to each table in order in the text of your article.

Please can you expand the titles of your tables. Please bear in mind that the title should be sufficiently detailed so that the table stands alone from the main text. Consider including additional detail because without this the reader

will need to refer to the main text to understand the table. Please also explain any abbreviations and symbols, if applicable.

**Reviewers:** Thank you for suggesting five potential reviewers. Once we proceed to the next stage, these will be checked by the editorial team to ensure they meet our [criteria](#).

**Payment:** As F1000Research is open access, we will require payment of the Article Processing Charge (APC) to be able to complete the processing of your submission. The APC is \$1350.00 after any discounts you are eligible for have been applied. **Please provide us with the details of the individual/organization taking responsibility for paying the fee as soon as possible.** Please sign in with the credentials you used to submit the article or you will not be able to access this page. Our Accounts department will be in touch regarding payment.

We have also lightly copyedited your article - please [download the document](#) and check you are happy with the amendments and **then address the queries detailed above using track changes in Word. Please return your revised manuscript to the e-mail address above.** Please note that this is your final opportunity to make any changes to the content of your manuscript. Once the typeset PDF of your manuscript has been created, we will send you a final PDF proof for checking prior to publication.

Best wishes,

Lisa  
The Editorial Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Do not delete (filing code): F1KR00CDE F1R-VER57248-A (end code)



---

## Payment for article APC in F1000Research (Article ID: 53825)

1 pesan

---

<info@f1000.com>

Kam, 1 Jul 2021 pukul 11.46

Kepada: andrianto@fk.unair.ac.id

Dear Andrianto

Mesenchymal Stem Cell Therapy Efficacy in COVID-19 Patients: A systematic review and meta-analysis  
Andrianto A, Cempaka Sari DKS, Al Farabi MJ, Yusrizal T and Hermawan HO

You have stated that you are the individual responsible for payment of the invoice for the article processing charge (APC) for the above article. Please note that the article has not yet been accepted; the invoice will be raised when the article is accepted by F1000Research, at which point our Accounts team will be in touch.

The details provided are:

Andrianto  
Department of Cardiology and Vascular Medicine, Airlangga University  
Prof Moestopo Street 5-7

60825  
Indonesia

The APC for this article, once any discounts have been taken into account, is \$1350.00

If you have any questions, please [contact us](#) as soon as possible.

Best regards

The F1000Research team

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Do not delete (filing code): F1KR00CDE F1R-VER57248-A (end code)



---

## Your article is now published

1 pesan

---

<production@f1000research.com>  
Kepada: andrianto@fk.unair.ac.id

Rab, 22 Sep 2021 pukul 19.19

Dear Andrianto,

I'm pleased to let you know that your article: "Mesenchymal stem cell therapy efficacy in COVID-19 patients: A systematic review and meta-analysis" has just been [published on F1000Research](#).

### The Peer Review Process

We are now inviting the reviewers you have suggested. As part of their reports, reviewers are asked to provide a recommendation of 'Approved', 'Approved with Reservations' or 'Not Approved', and their report will be published alongside the article with their full name and affiliation. You will be able to respond to any published reports with a comment and/or by publishing revisions as a new version of your article – we will send you instructions on how to proceed when you begin to receive reports.

It is important that authors do not contact the reviewers directly, as this could result in invalidating their report.

**Please note** that we will ask you for additional reviewer suggestions if the invited reviewers decline. In order to avoid any delays with the peer review of your article, please continue to check your [Suggest Reviewers](#) page for updates and respond to any email requests as soon as you can.

### Linking Your Data

Now that your article has been published and assigned a DOI ([10.12688/f1000research.53825.1](https://doi.org/10.12688/f1000research.53825.1)) we would strongly recommend that you include this DOI in the metadata of any published dataset associated with this article. If you would like assistance with this, please [contact our editorial team](#).

### Increasing Discoverability

Now that your article has been published, why not take advantage of the tools we provide to help maximize your article's reach and share your article using the Email and Share options on the article page.

Your article will be listed in ePMC shortly as a preprint, and then updated once it has passed peer review.

Regards

Zena Nyakoojo  
Senior Managing Editor, F1000Research

**Press releasing articles:** Please avoid promoting articles in the media until the article has passed the [open peer review process](#). Promotion on social media is encouraged once the article has been published; please ensure the full citation is included, as this contains the peer review status. F1000Research should be cited as the source of these articles with a link to the article.

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Do not delete (filing code): F1KR00CDE F1R-VER57248-A (end code)